Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone832-384-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.12 million
Profitability
Miscellaneous
Employees173
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.28. The biopharmaceutical company earned $0.52 million during the quarter, compared to the consensus estimate of $0.20 million. Bellicum Pharmaceuticals had a negative net margin of 6,729.02% and a negative return on equity of 123.00%. View Bellicum Pharmaceuticals' Earnings History.
When is Bellicum Pharmaceuticals' next earnings date?
What price target have analysts set for BLCM?
2 brokers have issued 12 month price targets for Bellicum Pharmaceuticals' stock. Their predictions range from $18.00 to $19.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $18.50 in the next year. This suggests a possible upside of 582.7% from the stock's current price. View Analyst Price Targets for Bellicum Pharmaceuticals.
What is the consensus analysts' recommendation for Bellicum Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellicum Pharmaceuticals.
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
News coverage about BLCM stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near term.
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include GlycoMimetics (GLYC), Akorn (AKRX), Revance Therapeutics (RVNC), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Synthorx (THOR), CytomX Therapeutics (CTMX), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), Corium International (CORI), NuCana (NCNA), Corbus Pharmaceuticals (CRBP), ProQR Therapeutics (PRQR), Evolus (EOLS) and Vital Therapies (VTL).
What other stocks do shareholders of Bellicum Pharmaceuticals own?
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
- Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
- Mr. Thomas J. Farrell, Consultant (Age 56)
- Mr. Atabak Mokari, Chief Financial Officer (Age 42)
- Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.
Who are Bellicum Pharmaceuticals' major shareholders?
Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (9.12%), BlackRock Inc. (6.25%), ARK Investment Management LLC (3.00%), Nikko Asset Management Americas Inc. (2.39%), Sumitomo Mitsui Trust Holdings Inc. (2.31%) and Renaissance Technologies LLC (2.14%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer, Jon P Stonehouse and Ken Moseley. View Institutional Ownership Trends for Bellicum Pharmaceuticals.
Which institutional investors are selling Bellicum Pharmaceuticals stock?
BLCM stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Morgan Stanley, Jefferies Group LLC, Franklin Street Advisors Inc. NC, FMR LLC, Virtu Financial LLC and California State Teachers Retirement System. Company insiders that have sold Bellicum Pharmaceuticals company stock in the last year include Alan A Musso and David M Spencer. View Insider Buying and Selling for Bellicum Pharmaceuticals.
Which institutional investors are buying Bellicum Pharmaceuticals stock?
BLCM stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Renaissance Technologies LLC, ARK Investment Management LLC, Oxford Asset Management LLP, JPMorgan Chase & Co., Shufro Rose & Co. LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Bellicum Pharmaceuticals.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $2.71.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $124.68 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.
What is Bellicum Pharmaceuticals' official website?
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
